152 related articles for article (PubMed ID: 30832965)
1. Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study.
Bullement A; Latimer NR; Bell Gorrod H
Value Health; 2019 Mar; 22(3):276-283. PubMed ID: 30832965
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V; Kurt M; Zhang L; Butler MO; Michielin O; Amadi A; Hernlund E; Johnson HM; Kotapati S; Moshyk A; Borrill J
MDM Policy Pract; 2022; 7(1):23814683221089659. PubMed ID: 35356551
[TBL] [Abstract][Full Text] [Related]
3. A review and validation of overall survival extrapolation in health technology assessments of cancer immunotherapy by the National Institute for Health and Care Excellence: how did the initial best estimate compare to trial data subsequently made available?
Bullement A; Meng Y; Cooper M; Lee D; Harding TL; O'Regan C; Aguiar-Ibanez R
J Med Econ; 2019 Mar; 22(3):205-214. PubMed ID: 30422080
[TBL] [Abstract][Full Text] [Related]
4. Predicting analysis times in randomized clinical trials with cancer immunotherapy.
Chen TT
BMC Med Res Methodol; 2016 Feb; 16():12. PubMed ID: 26830911
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence.
Giannopoulou C; Sideris E; Wade R; Moe-Byrne T; Eastwood A; McKenna C
Pharmacoeconomics; 2015 Dec; 33(12):1269-79. PubMed ID: 26043718
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
7. How accurate are the longer-term projections of overall survival for cancer immunotherapy for standard versus more flexible parametric extrapolation methods?
Cooper M; Smith S; Williams T; Aguiar-Ibáñez R
J Med Econ; 2022; 25(1):260-273. PubMed ID: 35060433
[TBL] [Abstract][Full Text] [Related]
8. The Option Value of Innovative Treatments for Metastatic Melanoma.
Thornton Snider J; Seabury S; Tebeka MG; Wu Y; Batt K
Forum Health Econ Policy; 2018 Jun; 21(1):. PubMed ID: 30210050
[TBL] [Abstract][Full Text] [Related]
9. Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
Ouwens MJNM; Mukhopadhyay P; Zhang Y; Huang M; Latimer N; Briggs A
Pharmacoeconomics; 2019 Sep; 37(9):1129-1138. PubMed ID: 31102143
[TBL] [Abstract][Full Text] [Related]
10. What Did Time Tell Us? A Comparison and Retrospective Validation of Different Survival Extrapolation Methods for Immuno-Oncologic Therapy in Advanced or Metastatic Renal Cell Carcinoma.
Klijn SL; Fenwick E; Kroep S; Johannesen K; Malcolm B; Kurt M; Kiff C; Borrill J
Pharmacoeconomics; 2021 Mar; 39(3):345-356. PubMed ID: 33428174
[TBL] [Abstract][Full Text] [Related]
11. Are tumor size changes predictive of survival for checkpoint blockade based immunotherapy in metastatic melanoma?
Wang M; Chen C; Jemielita T; Anderson J; Li XN; Hu C; Kang SP; Ibrahim N; Ebbinghaus S
J Immunother Cancer; 2019 Feb; 7(1):39. PubMed ID: 30736858
[TBL] [Abstract][Full Text] [Related]
12. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
13. Accounting for Cured Patients in Cost-Effectiveness Analysis.
Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
[TBL] [Abstract][Full Text] [Related]
14. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
15. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of melanoma combination immunotherapy.
Baker H
Lancet Oncol; 2017 Oct; 18(10):e565. PubMed ID: 28870612
[No Abstract] [Full Text] [Related]
17. Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit.
Péron J; Lambert A; Munier S; Ozenne B; Giai J; Roy P; Dalle S; Machingura A; Maucort-Boulch D; Buyse M
J Natl Cancer Inst; 2019 Nov; 111(11):1186-1191. PubMed ID: 30838402
[TBL] [Abstract][Full Text] [Related]
18. A Case Study Examining the Usefulness of Cure Modelling for the Prediction of Survival Based on Data Maturity.
Grant TS; Burns D; Kiff C; Lee D
Pharmacoeconomics; 2020 Apr; 38(4):385-395. PubMed ID: 31848900
[TBL] [Abstract][Full Text] [Related]
19. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
[TBL] [Abstract][Full Text] [Related]
20. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Maio M; Grob JJ; Aamdal S; Bondarenko I; Robert C; Thomas L; Garbe C; Chiarion-Sileni V; Testori A; Chen TT; Tschaika M; Wolchok JD
J Clin Oncol; 2015 Apr; 33(10):1191-6. PubMed ID: 25713437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]